JCJulia Carrasco-Zanini

Julia Carrasco-Zanini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julia Carrasco-Zanini has a total of 164 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Proteomics identify disease-associated variants in patients with rare diseases undiagnosed after genome sequencing

    by Julia Carrasco-Zanini, Jorge Andrade, Maik Pietzner, Athanasios Kousathanas, Julius O. B. Jacobsen, Jenny Lord, Narasimha Telugu, Sebastian Diecke, Michael Mülleder, Dominik Bierbaum, et al.

    Despite the introduction of genome sequencing (GS) for rare disease diagnostics, a genetic cause is not identified in most patients. Here, we explored the potential of proteomics to improve the diagnostic yield in 424 patients with rare diseases from the 100,000 Genomes Project (100kGP) without a genetic diagnosis. Serum proteomic profiling was performed using the Olink Explore 1536 assay ( N = 1463 proteins). For 13 patients without genetic diagnoses, detection of lower serum protein “outliers” ( z -score < −2) led to confirmed genetic diagnoses by resolving variants of uncertain significance or prioritizing genes for targeted GS reanalysis. For 23 additional patients without genetic diagnoses (64% of findings), we identified candidate gene-disease links and variants through convergent evidence from lower protein outliers and variants ranked through the variant prioritization tool Exomiser. For example, we identified a candidate heterozygous missense variant [Genome Aggregation Database (gnomAD) minor allele frequency = 0.006%] in tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains 1 ( TIE1 ) that was only present in a patient with lower TIE1 serum abundance ( z -score = −5.12) and their father, both of whom were affected by the same monogenic cardiac disorder, but in no other individuals from the 100kGP. Missense (52.5%) and splice region (27.5%) variants accounted for most diagnostic or candidate variants prioritized. This proof-of-principle study demonstrated that serum proteomics can support rare disease diagnosis and identify disease-causing genes in patients undiagnosed after GS, although successful implementation will likely depend on tissue specificity of protein expression, detectability in blood, proteomic platform coverage, and sensitivity.

  • Open Access

    Nanoparticle-enriched mass spectrometry proteomics in British South Asians identifies links between genetic variants, plasma protein levels and disease risk

    by Maik Pietzner, Alice Williamson, Karen A. Hunt, Mine Koprulu, Leonhard Kohleick, Kamil Demircan, David A. van Heel, Sarah Finer, Julia Carrasco Zanini, Claudia Langenberg

    Understanding genetic variation associated with differences in plasma protein levels can elucidate human disease mechanisms. Here we demonstrate how untargeted nanoparticle-enriched mass spectrometry (MS)-based plasma proteomics delivers quantitatively and qualitatively different insights compared to two affinity-based assays in a sample of ~1,400 British South Asian individuals. We identify >1,200 significant locus–protein associations ( P < 8.7 × 10 −12 ; n = 895 cis -protein quantitative trait loci (pQTLs)), more than half of which have not been reported previously. Cross-platform comparison demonstrated that multiple platforms are required to capture the full spectrum of pQTLs of blood proteins. We combine proteogenomic results with evidence from multiple biological domains to suggest a potential role of 21 proteins in the pathology of 44 diseases, including a previously uncharacterized role of immunoglobulin λ variable 3-21 in the development of Graves’ disease. Our results demonstrate the potential of MS-based blood proteomics in non-European ancestries for pQTL discovery and the need to consolidate proteogenomic evidence to confidently assign proteins to disease pathology.


  • Open Access

    Tissue origins of the plasma proteomic response to glucose ingestion in humans

    by Burulça Uluvar, Alice Williamson, Kristoffer J. Kolnes, Per Bendix Jeppesen, Anders J. Kolnes, Mine Koprulu, Martijn Zoodsma, Carl Beuchel, Yanki Bambal, Mar Reines, et al.

    Aims/hypothesis: Circulating proteins act as important hormonal signals of nutrient intake. We aimed to systematically characterise the time-resolved proteomic response to glucose ingestion in humans, and to assess its robustness following prolonged complete caloric restriction. Methods: We conducted oral glucose tolerance tests (OGTTs) in 11 healthy volunteers before and after 7 days of complete caloric restriction and measured the response of >2900 targets through high-resolution plasma protein profiling. Results: We identified a signature of 44 proteins that changed significantly following glucose ingestion, which was reproducible after 7 days without food, and was strongly (20-fold) enriched for ‘stomach-specific’ proteins. We report that annexin A10 (ANXA10) shows the most significant post-glucose change observed, similar to the trajectories of secreted hormones. We present observational human evidence from multiple sources suggesting that ANXA10 is secreted upon sensing an increase in gastric pH, with the stomach as the major contributing tissue. Despite a profound metabolic shift after 7 days of complete caloric restriction, characterised by delayed insulin secretion and postprandial hyperglycaemia, only four proteins showed robust evidence for a differential trajectory during both OGTTs. This included plasma levels of tryptophanyl-tRNA synthetase 1 (WARS), for which we found a genetic association with glucose homeostasis and coronary artery disease. Conclusions/interpretation: Our exploratory study identifies the proteomic response to glucose ingestion and demonstrates its reproducibility despite major shifts in glucose homeostasis. We characterise the gastrointestinal origin of these changes, and hypothesise a hitherto under-recognised role for sensing of changes in gastric pH on the plasma proteome.

  • Open Access

    Data-driven prioritization of high-risk individuals for weight loss interventions

    by Kamil Demircan, Julia Carrasco-Zanini, Alice Williamson, Carl Beuchel, Linsey Jackson, Werner Römisch-Margl, Aleksander L. Hansen, Sarah Finer, David A. van Heel, Gabi Kastenmüller, et al.

    New obesity medications have demonstrated efficacy in trials, but their real-world deployment is partly limited by the absence of approaches that identify individuals for treatment based on risks for obesity-related complications. Here we present a risk prediction model to guide prioritization of high-risk individuals. In a population-based sample of ~200,000 individuals with a body mass index (BMI) exceeding 27 kg m − 2 , our machine learning framework identified the 20 most informative features, from among thousands tested, that predict future onset of 18 complications of obesity, providing information beyond BMI. An integrated model (OBSCORE) successfully stratified individuals into risk groups based on incidence over 10 years: for example, 5.7%, 1.8%, 0.9%, 0.4% and 0.1% for cardiovascular mortality. We demonstrate generalizability of the model in independent populations of European and non-European ancestry and, in SURMOUNT-1 trial participants, show that weight loss was similar across baseline OBSCORE risk groups and that predicted risks decreased following treatment with tirzepatide. In summary, OBSCORE provides a framework for prioritizing high-risk individuals with overweight or obesity based on their risk of obesity-related complications, complementing BMI-based frameworks.


  • Open Access

    An ancestry-enriched PIEZO1 missense variant biases HbA1c-based diagnosis of prediabetes and type 2 diabetes in South Asians

    by Miriam Samuel, Daniel Stow, Vi Bui, Margherita Bigossi, Sam Hodgson, Susan Martin, Jana Soenksen, Camila Armirola-Ricaurte, Stuart Rison, Julia Cassasco-Zanini, et al.

    Background: Glycated haemoglobin (HbA1c) underpins type 2 diabetes (T2D) and prediabetes management worldwide and reflects both glycaemia and erythrocyte biology. A missense variant in PIEZO1 (rs563555492 T ), carried by 1 in 12 south Asians, has been associated with a nonglycemic reduction in HbA1c. We aimed to further characterise this association and evaluate its clinical consequences. Methods: We undertook genetic and linked health data analyses across two cohorts: 19,898 (37.4% female) South Indians from the Madras Diabetes Research Foundation (MDRF) and 43,011 (54.4% female) British Bangladeshis and British Pakistanis in Genes & Health. In MDRF, we tested associations with glycaemic and erythrocytic traits using additive genetic models. In Genes & Health we modelled diagnosis of prediabetes, T2D, and diabetic eye disease using flexible parametric survival models. Ten-year absolute risks were estimated for a population aged 40-50 years. Findings: PIEZO1 rs563555492 T was associated with erythrocytic traits and lower HbA1c, but not with fasting glucose, postprandial glucose, or C-peptide. This variant reduced risk of prediabetes (HR 0·63, 95% CI 0·58-0·69) and T2D (0·85, 0·78-0·93) diagnosis, and increased risk of diabetic eye disease among individuals with T2D (1·20, 1·01-1·43). Modelling suggested approximately 1,019 missed prediabetes and 303 missed T2D diagnoses per 100,000 adults over 10 years. Interpretation: An ancestry enriched PIEZO1 variant is associated with lower HbA1c independent of glycaemia, reduced prediabetes and T2D diagnosis suggesting delayed detection, and increased complication risk. Reliance on HbA1c may systematically underestimate glycaemic risk in a substantial minority of south Asians. Funding: The Wellcome Trust; NIHR Research in Context: Evidence before this study: We searched PubMed from database inception to Nov 1, 2025, for studies examining PIEZO1, Glycated Haemoglobin (HbA1c) and type 2 diabetes (T2D) related outcomes. Search terms included “PIEZO1”, “haemoly*”, “hemol*”, “erythrocyte*”, “HbA1c”, “glycated haemoglobin”, “glycated hemoglobin”, “type 2 diabetes”, “prediabetes”, “retinopathy”, and related terms. HbA1c is widely used to guide prevention, diagnosis, and management of T2D, but variants affecting erythrocyte structure or lifespan can alter its relationship with glycaemia. A missense variant in PIEZO1 (rs563555492 T ), carried by one in twelve south Asians, has been associated with lower HbA1c and erythrocytic biomarkers without differences in fasting glucose and with older age at T2D diagnosis, suggesting delayed diagnosis in UK-based cohorts. However, uncertainties remain. Associations have not been replicated outside the UK to confirm generalisability. Experimental animal models suggest PIEZO1 channels may influence pancreatic insulin secretion, but this has not been evaluated in human cohorts. Finally, the potential clinical and health-economic consequences associated with this variant remain largely unexplored. Added value of this study: We replicated associations between rs563555492 T , lower HbA1c, and erythrocytic changes in a geographically distinct south Asian cohort based in South India. We found no association with fasting glucose, postprandial glucose, or C-peptide concentrations, supporting a predominantly erythrocytic mechanism. We examined the clinical and economic consequences of this variant on south Asians in a large UK population-based cohort, following introduction of HbA1c-based diagnostic criteria. Carriers experienced delayed diagnosis of prediabetes and T2D, and there was some evidence of increased risk of diabetic eye disease. In a modelled population aged 40-50 years, the variant was associated with approximately 1,019 missed prediabetes diagnoses and 303 missed T2D diagnoses per 100,000 adults over 10 years. Because prediabetes diagnosis initiates referral to prevention programmes, missed diagnoses represent lost opportunities for disease prevention. In a UK NHS setting, we estimated the associated opportunity cost to be between £970,000 - £1,390,000 per 100,000 individuals over a 10-year horizon. Implications of all the available evidence: A south Asian ancestry enriched PIEZO1 variant can disrupt the relationship between HbA1c and glycaemia and delay detection of prediabetes and T2D. Reliance on HbA1c alone may underestimate glycaemic risk in a substantial minority of individuals of south Asian ancestry, with potential implications for prevention strategies, risk of complications and health care costs. Alternative biomarkers of glycaemia or individualisation of HbA1c may help ensure timely and accurate diabetes detection in populations where this variant is common.

  • Top Cited Papers

    Five tenets for advancing evidence-based precision medicine

    by Daniel E. Coral, Jennifer L. Sargent, Julia Carrasco-Zanini, Luis M. Coral, Aaron J. Deutsch, Miriam S. Udler, Giuseppe N. Giordano, Guillaume Pare, Ewan R. Pearson, Maarten van Smeden, et al.

    Precision medicine for complex diseases uses individual-level characteristics to improve prediction of risk, therapeutic response and prognosis. Many precision medicine studies leverage existing data types and analytic methods to reveal new insights; however, beyond oncology, there has been limited success in translating precision medicine research for complex diseases into clinical practice. Thus, there is a need to identify areas for improvement, particularly in translation-oriented analytical methods and study designs. In this perspective article, we outline five fundamental tenets to enhance the efficient clinical translation of precision medicine research. These tenets focus on addressing (1) heterogeneity in risk, response and prognosis; (2) signal robustness; (3) structured statistical benchmarking against key performance indicators; (4) precision trial designs; and (5) risks and benefits to individuals and society. Our intention is to promote clinically meaningful, reproducible, scalable and equitable health outcomes through precision medicine, beyond those possible through contemporary approaches.


  • Open Access

    Proteomic and clinical impact of human knockouts in British South Asians

    by Julia Carrasco Zanini, Maik Pietzner, Mine Koprulu, Martijn Zoodsma, Alice Williamson, Karen A. Hunt, Angelos Manolias, Klaudia Walter, Hilary C. Martin, Sarah Finer, et al.

    Human loss-of-function (LoF) variants affecting both copies of a gene (“human knockouts”) provide a unique opportunity to directly study function and clinical impact of genes but are very rare in most populations sequenced to date. Here we study 1,569 British Bangladeshi and -Pakistani adults who were recalled for plasma sampling for proteomic profiling using three distinct technologies (covering >12,000 proteins) from 55k whole exome sequenced Genes & Health adults – a cohort enriched for rare, biallelic (homozygous) variants due to high autozygosity. We identified 199 individuals with rare homozygous predicted LoF genotypes (pLoF) for which the respective cis- protein was measured by at least one technology, and observed extreme (> 3SDs) cis- protein underexpression in 41 individuals (median z-score = −9.72 (range: −19.61 to −4.78) and overexpression in 2 individuals (median z-score = 8.1 (range 4.80 – 11.40)), representing 19% of these variants. For missense homozygotes, we observed 158 individuals with significantly under-expressed cis- protein (median z-score = −6.95 (range: −28.16 to −3.95)) and 62 individuals over-expressed, median z-score = 5.65 (range: 4.57 to 25.08)). The majority (62%) of LoF knockout genes with an identified cis-protein effect had evidence from 2 or more platforms, highlighting the high confidence nature of these discoveries. Systematic clinical assessment of human knockouts with strong evidence of an impact on cis- protein abundance through multi-source electronic health record linkage enabled identification of 1) knockout carriers with rare disease features based on phenotypic similarity, 2) novel rare disease-causing variants, 3) evidence for reclassification of genes and variants of uncertain significance from ClinVar and rare disease panels, and 4) novel gene-phenotype associations in humans. Based on high confidence examples, we developed a machine learning model that predicted 1 in 4 pLOF and 9 in 10 missense variants are likely benign. In summary, our study provides strong human-derived insights into the fundamental biology and clinical relevance of many genes and shows the value of proteogenomic studies of human knockout carriers.


  • Open Access

    Sex differences in the genetic regulation of the human plasma proteome

    by Mine Koprulu, Eleanor Wheeler, Nicola D. Kerrison, Spiros Denaxas, Julia Carrasco-Zanini, Chloe M. Orkin, Harry Hemingway, Nicholas J. Wareham, Maik Pietzner, Claudia Langenberg

    Mechanisms underlying sex differences in the development and prognosis of many diseases remain largely elusive. Here, we systematically investigated sex differences in the genetic regulation of plasma proteome (>5800 protein targets) across two cohorts (30,307 females; 26,058 males). Plasma levels of two-thirds of protein targets differ significantly by sex. In contrast, genetic effects on protein targets are remarkably similar across sexes, with only 103 sex-differential protein quantitative loci (sd-pQTLs; for 2.9% and 0.3% of protein targets from antibody- and aptamer-based platforms, respectively). A third of those show evidence of sexual discordance, i.e., effects observed in one sex only (n = 30) or opposite effect directions (n = 1 for CDH15). Phenome-wide analyses of 365 outcomes in UK Biobank did not provide evidence that the identified sd-pQTLs accounted for sex-differential disease risk. Our results demonstrate similarities in the genetic regulation of protein levels by sex with important implications for genetically-guided drug target discovery and validation.


  • Top Cited Papers
    Open Access

    Integrative proteogenomic analysis identifies COL6A3-derived endotrophin as a mediator of the effect of obesity on coronary artery disease

    by Satoshi Yoshiji, Tianyuan Lu, Guillaume Butler-Laporte, Julia Carrasco-Zanini-Sanchez, Chen-Yang Su, Yiheng Chen, Kevin Liang, Julian Daniel Sunday Willett, Shidong Wang, Darin Adra, et al.

    Obesity strongly increases the risk of cardiometabolic diseases, yet the underlying mediators of this relationship are not fully understood. Given that obesity strongly influences circulating protein levels, we investigated proteins mediating the effects of obesity on coronary artery disease, stroke and type 2 diabetes. By integrating two-step proteome-wide Mendelian randomization, colocalization, epigenomics and single-cell RNA sequencing, we identified five mediators and prioritized collagen type VI α3 (COL6A3). COL6A3 levels were strongly increased by body mass index and increased coronary artery disease risk. Notably, the carboxyl terminus product of COL6A3, endotrophin, drove this effect. COL6A3 was highly expressed in disease-relevant cell types and tissues. Finally, we found that body fat reduction could reduce plasma levels of COL6A3-derived endotrophin, indicating a tractable way to modify endotrophin levels. In summary, we provide actionable insights into how circulating proteins mediate the effects of obesity on cardiometabolic diseases and prioritize endotrophin as a potential therapeutic target.


  • Top Cited Papers
    Open Access

    Proteomic signatures improve risk prediction for common and rare diseases

    by Julia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, Praveen Surendran, Damien C. Croteau-Chonka, Chloe Robins, Ana Torralbo, Christopher Tomlinson, Florian Grünschläger, Natalie Fitzpatrick, et al.

    For many diseases there are delays in diagnosis due to a lack of objective biomarkers for disease onset. Here, in 41,931 individuals from the United Kingdom Biobank Pharma Proteomics Project, we integrated measurements of ~3,000 plasma proteins with clinical information to derive sparse prediction models for the 10-year incidence of 218 common and rare diseases (81–6,038 cases). We then compared prediction models developed using proteomic data with models developed using either basic clinical information alone or clinical information combined with data from 37 clinical assays. The predictive performance of sparse models including as few as 5 to 20 proteins was superior to the performance of models developed using basic clinical information for 67 pathologically diverse diseases (median delta C-index = 0.07; range = 0.02–0.31). Sparse protein models further outperformed models developed using basic information combined with clinical assay data for 52 diseases, including multiple myeloma, non-Hodgkin lymphoma, motor neuron disease, pulmonary fibrosis and dilated cardiomyopathy. For multiple myeloma, single-cell RNA sequencing from bone marrow in newly diagnosed patients showed that four of the five predictor proteins were expressed specifically in plasma cells, consistent with the strong predictive power of these proteins. External replication of sparse protein models in the EPIC-Norfolk study showed good generalizability for prediction of the six diseases tested. These findings show that sparse plasma protein signatures, including both disease-specific proteins and protein predictors shared across several diseases, offer clinically useful prediction of common and rare diseases.